AHCPR to Fund Analysis of the Impact of Managed Care&#x27;s Growth

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD

December 1st 2025

Laparoscopic Distal Gastrectomy Appears Feasible in T4a Gastric Cancer

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Russ Conroy

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD

November 24th 2025

Investigational Cell Therapy Yields Durable Complete Response in BCG-Naïve NMIBC

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

During treatment with TARA-002, there were no grade 3 or higher TRAEs, and TRAEs did not lead to any treatment discontinuations in patients with BCG-naïve NMIBC.

Tim Cortese

FDA Gives Traditional Approval to Pirtobrutinib in CLL/SLL

During treatment with TARA-002, there were no grade 3 or higher TRAEs, and TRAEs did not lead to any treatment discontinuations in patients with BCG-naïve NMIBC.

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.

Ariana Pelosci

Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.

Related Content

Andrea I. Nañez, MD;Maria C. Velez, MD;Mae Zakhour, MD;Edward B. Garon, MD, MS

December 4th 2025

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD

December 1st 2025

Laparoscopic Distal Gastrectomy Appears Feasible in T4a Gastric Cancer

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Russ Conroy

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD

November 24th 2025

Investigational Cell Therapy Yields Durable Complete Response in BCG-Naïve NMIBC

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Tim Cortese

FDA Gives Traditional Approval to Pirtobrutinib in CLL/SLL

During treatment with TARA-002, there were no grade 3 or higher TRAEs, and TRAEs did not lead to any treatment discontinuations in patients with BCG-naïve NMIBC.

Ariana Pelosci